GLSI
Greenwich LifeSciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is that FLAMINGO-01 operational momentum is improving: FDA cleared use of the first commercial GP2 lot, screening rose above 800 patients per year, the 250-patient open-label arm is fully enrolled, and company-reported early recurrence trends remain favorable versus historical benchmarks [#PR-2026-01-22] [#PR-2026-03-03] [#PR-2026-03-17].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.2.
What can break
Going-concern and dilution risk remain material despite January 2026 ATM progress [#10-Q-2025-11-14] [#PR-2026-01-27].
Momentum
83
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $12.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $47.50
Why
Momentum83 · Δ7d +5.2
Value41 · Δ7d +0.1
Sentiment52 · Δ7d +0.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
83
34% active weight
Current posture
7d trendFlat
Δ7d
+5.2
Δ21d
+37.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
52
33% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-8.6
Why this grade
Composite grade B. Momentum 83.1 / Value 41.1 / Sentiment 51.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$394.99M
Beta
1.45
Shares Out
13.85M
P/E (TTM) · Derived
-23.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-44.25
Rev YoY
-
EPS YoY
-49.9%
Gross Margin
-
Op Margin
-
Net Debt
-$4.09M
Current Ratio
2.35
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology

